{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-23-000056","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.119030+00:00","generated_at":"2026-06-09T19:40:41.045414+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC Therapeutics monetizes Evrysdi royalties for up to $1.5B, pays off Blackstone debt","bullets":["PTC receives $1.0B upfront for ~38% additional Evrysdi royalty; total ~81% sold to Royalty Pharma.","PTC can sell remaining royalty for up to $500M via puts through Dec 2025; Royalty Pharma may call up to $250M.","Proceeds to retire all Blackstone debt; Credit Agreement from Oct 2022 terminated.","PTC retains all economics on up to $250M in commercial sales milestones for Evrysdi."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-23-000056","json":"https://secwatch.observer/filing/0001070081-23-000056.json","markdown":"https://secwatch.observer/filing/0001070081-23-000056.md","text":"https://secwatch.observer/filing/0001070081-23-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000056/0001070081-23-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000056/tmb-20231018x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T19:40:41.045414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}